Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide

Although immune checkpoint inhibitors (ICI) have revolutionized cancer management, patient response can be heterogeneous, and the development of ICI resistance is increasingly reported. Novel treatment strategies are necessary not only to expand the use of ICI to previously unresponsive tumor types...

Descripción completa

Detalles Bibliográficos
Autores principales: de Aguiar Ferreira, Carolina, Heidari, Pedram, Ataeinia, Bahar, Sinevici, Nicoleta, Granito, Alyssa, Kumar, Hritik Mahajan, Wehrenberg-Klee, Eric, Mahmood, Umar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325142/
https://www.ncbi.nlm.nih.gov/pubmed/35890355
http://dx.doi.org/10.3390/pharmaceutics14071460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325142/
https://www.ncbi.nlm.nih.gov/pubmed/35890355
http://dx.doi.org/10.3390/pharmaceutics14071460

Ejemplares similares